Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer
Shots:
- Gaeta to receive $0.2M up front and is eligible to receive ~$7.5M in clinical and regulatory milestones based on product and indication
- The agreement will expand Oncorus clinical development of ONCR-177 for the treatment of cancer patients in combination with pembrolizumab and other immunotherapies, and also helps to bolster the commercialization strategy of the product
- Oncorus is currently enrolling the patients in a P-I clinical trial of ONCR-177 as monothx. and in combination with Merck's Keytruda for advanced & refractory solid tumors or with liver metastases. The results will be presented at SITC 2021
Ref: Globe Newswire | Image: Oncorus
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com